Evidence for sustained relief
Outcomes from a 2023 PROCURA study1 show that differential target multiplexed (DTM™) SCS therapy results in an 86.0% upper limb pain (ULP) responder rate with DTM™ SCS at 12 months for an improvement rate ≥50% (n = 43).1
PROCURA is an on-label, multicenter, observational clinical study using DTM™ SCS evaluating patients with intractable chronic upper limb pain (VAS ≥ 5 cm) at 11 sites across the United States.1
Upper limb pain relief§,‡
Sustained upper limb pain relief with a mean VAS score of 1.45 cm at
12 months with DTM™ SCS (n=43)
Upper limb pain
responder rate§
86% - ULP responder rate with DTM™ SCS at 12 months
(≥50% improvement). (n = 43)
Upper limb pain profound responder rate
(≥80% ULP pain relief)§
70% - 7 out of 10 patients were profound ULP responders (≥80% relief) with DTM at 12 months.
DTM therapy outcomes1
Subjects reporting ≥ 50% pain relief
91.5%
At 3-month
follow-up (n=47)
90.9%
At 6-month
follow-up (n=44)
86.0%
At 12-month
follow-up (n=43)
Quality-of-life outcomes†
DTM™ SCS provides effective upper limb pain (ULP) relief through 12 months.
- 86.0% ULP responder rate at 12 months.
- ULP visual analog scale (VAS) was reduced by 79.8%.
- Patients experienced a 29.6 point reduction in their reported PDI scores with DTM™ SCS.
- 94.9% of subjects were very satisfied with DTM™ SCS therapy at 12 months.
Talk with your Medtronic representative to learn more about SCS.
† Per protocol analysis. Trial phase completer’s analysis = Includes all subjects that completed the trial phase. Subjects that fail trial or discontinue due to lack of pain relief are included.
‡ ULP (n): Baseline (52), 3-month (47), 6-month (44), 12-month (43).
§ Trial phase completer’s analysis = Includes all subjects that completed the trial phase. Subjects that fail trial or discontinue due to lack of pain relief are included.
1
White T, et al. Effect of differential target multiplexed SCS on intractable upper limb pain: A 12-month prospective study. Presented at: North American Neuromodulation Society (NANS) Annual Meeting. Jan. 18-21, 2024. Las Vegas, NV, USA.